Nationwide Children's spinoff gets FDA OK to test persistent pneumonia treatment in humans

Clarametyx Biosciences Inc. announced Wednesday that the U.S. Food and Drug Administration accepted the Columbus company ’s application to test the safety of its treatment for antibiotic-resistant infections, in both healthy volunteers and patients hospitalized with pneumonia.

Source: bizjournals.com Health Care:Physician Practices headlines - October 6, 2022 Category: American Health Authors: Carrie Ghose Source Type: news